The stock of Allogene Therapeutics Inc (ALLO) has gone down by -14.92% for the week, with a -24.90% drop in the past month and a -22.21% drop in the past quarter. The volatility ratio for the week is 15.73%, and the volatility levels for the past 30 days are 9.65% for ALLO. The simple moving average for the last 20 days is -24.71% for ALLO stock, with a simple moving average of -50.04% for the last 200 days.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
The stock has a 36-month beta value of 0.34. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ALLO is 143.20M, and at present, short sellers hold a 21.04% of that float. On May 13, 2025, the average trading volume of ALLO was 5.64M shares.
ALLO) stock’s latest price update
Allogene Therapeutics Inc (NASDAQ: ALLO) has seen a decline in its stock price by -6.92 in relation to its previous close of 1.17. However, the company has experienced a -14.92% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-06 that Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Citizens JMP repeating the rating for ALLO by listing it as a “Mkt Outperform.” The predicted price for ALLO in the upcoming period, according to Citizens JMP is $5 based on the research report published on March 14, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11, previously predicting the price at $13. The rating they have provided for ALLO stocks is “Outperform” according to the report published on August 08th, 2024.
Piper Sandler gave a rating of “Overweight” to ALLO, setting the target price at $11 in the report published on May 31st of the previous year.
ALLO Trading at -31.01% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.19% of loss for the given period.
Volatility was left at 9.65%, however, over the last 30 days, the volatility rate increased by 15.73%, as shares sank -23.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.17% lower at present.
During the last 5 trading sessions, ALLO fell by -14.45%, which changed the moving average for the period of 200-days by -62.37% in comparison to the 20-day moving average, which settled at $1.4468. In addition, Allogene Therapeutics Inc saw -48.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Yoshiyama Annie, who sale 9,601 shares at the price of $1.41 back on Apr 21 ’25. After this action, Yoshiyama Annie now owns 130,663 shares of Allogene Therapeutics Inc, valued at $13,537 using the latest closing price.
Yoshiyama Annie, the Officer of Allogene Therapeutics Inc, proposed sale 9,601 shares at $1.41 during a trade that took place back on Apr 21 ’25, which means that Yoshiyama Annie is holding shares at $13,537 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -12418.14 for the present operating margin
- 1.0 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -11708.64. The total capital return value is set at -0.53. Equity return is now at value -55.13, with -43.24 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -2.21. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -1509.39.
Currently, EBITDA for the company is -243.33 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 11641.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.54.
Conclusion
To sum up, Allogene Therapeutics Inc (ALLO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
